AI

What are some commonly used antibodies against IGF-1 and IGF-2?

Reference

Most of the circulating IGF-1 and IGF-2 are associated with a high molecular weight complex ~150 kDa consisting of IGFBP ... The most commonly used strategy is engineered antibodies or antibody ... In some instances, IGF-2 action via the IR-A also promotes resistance to anti-IGF-1R inhibitors. Thus, specific therapeutic combinations can be an

www.ncbi.nlm.nih.gov

Anti-ligand antibodies, developed to mimic IGFBP action, have a high affinity against both IGF-1 and IGF-2, and do not cross-react with insulin [224-226]. Several antibodies targeting IGF-1 or IGF-2 have been reported, with one reaching clinical trial . They prevent signaling through the IGF-1R and the hybrid receptors, but, importantly, they

pmc.ncbi.nlm.nih.gov

PPP is an orally active IGF-1R inhibitor found to be effective to some extent toward IR, fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptor (PDGFR). ... A third method recently described to neutralize the ligand is the use of antibodies against IGF-1 and IGF-2 . A rat monoclonal antibody, KM1468, which

link.springer.com

Reference

Most of the circulating IGF-1 and IGF-2 are associated with a high molecular weight complex ~150 kDa consisting of IGFBP ... The most commonly used strategy is engineered antibodies or antibody ... In some instances, IGF-2 action via the IR-A also promotes resistance to anti-IGF-1R inhibitors. Thus, specific therapeutic combinations can be an

www.ncbi.nlm.nih.gov

Anti-ligand antibodies, developed to mimic IGFBP action, have a high affinity against both IGF-1 and IGF-2, and do not cross-react with insulin [224-226]. Several antibodies targeting IGF-1 or IGF-2 have been reported, with one reaching clinical trial . They prevent signaling through the IGF-1R and the hybrid receptors, but, importantly, they

pmc.ncbi.nlm.nih.gov

PPP is an orally active IGF-1R inhibitor found to be effective to some extent toward IR, fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptor (PDGFR). ... A third method recently described to neutralize the ligand is the use of antibodies against IGF-1 and IGF-2 . A rat monoclonal antibody, KM1468, which

link.springer.com

OpenAI's Answer

Some commonly used antibodies against IGF-1 and IGF-2 include:

KM1468: A rat monoclonal antibody mentioned as being used to neutralize the ligand is effective against both IGF-1 and IGF-2. Source.
m708.5: A novel human monoclonal antibody that targets IGF-I/II-neutralizing activity, used in oncological contexts for inhibiting tumor growth. Source.
BI 836845: A candidate therapeutic antibody that targets both IGF-1 and IGF-2, currently examined for its interactions with IGF-1:IGFBP-3 complexes. Source.
Anti-IGF-1R Antibodies: Therapeutic antibodies directed against the insulin-like growth factor receptor (IGF-1R) have shown promise in inhibiting cancer growth by preventing IGF-mediated signaling. Source.

These antibodies are often part of therapeutic approaches targeting the Insulin-like Growth Factor system for the treatment of various cancers.

Here are some relevant images:

IGF Antibody Western Blot IGF Signaling Pathway Anti-IGF Antibodies Tumor Inhibition

For further reading, you can explore more about these antibodies and their clinical applications in the mentioned sources.

Follow Up

Related

Lý do chọn đề tài: chứng minh" nhận định hiệu quả kinh doanh bán hàng chỉ thực sự hiệu quả nếu tạo r

Elabora una tabla comparativa, con cuatro columnas (autor, personajes, estilos de narración y elemen

layla ai asistente offline en español

pte

A continuación resolver las Preguntas por Actua como ingeniero ambiental senior, y tratemos de a

©2024 AskWiki.Ai